Thromboembolic Disease in Patients With Cancer and COVID-19 : Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Anticancer research - 42(2022), 7 vom: 26. Juli, Seite 3261-3274 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 06.07.2022 Date Revised 08.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/anticanres.15815 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343109190 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343109190 | ||
| 003 | DE-627 | ||
| 005 | 20231226015650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/anticanres.15815 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343109190 | ||
| 035 | |a (NLM)35790272 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dimakakos, Evangelos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thromboembolic Disease in Patients With Cancer and COVID-19 |b Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2022 | ||
| 500 | |a Date Revised 08.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anticoagulation | |
| 650 | 4 | |a CAT | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a review | |
| 650 | 4 | |a thromboprophylaxis | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Gomatou, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Catalano, Mariella |e verfasserin |4 aut | |
| 700 | 1 | |a Olinic, Dan-Mircea |e verfasserin |4 aut | |
| 700 | 1 | |a Spyropoulos, Alex C |e verfasserin |4 aut | |
| 700 | 1 | |a Falanga, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Maraveyas, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Schulman, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Belch, Jill |e verfasserin |4 aut | |
| 700 | 1 | |a Gerotziafas, Grigorios |e verfasserin |4 aut | |
| 700 | 1 | |a Marschang, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Cosmi, Benilde |e verfasserin |4 aut | |
| 700 | 1 | |a Spaak, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Syrigos, Konstantinos |e verfasserin |4 aut | |
| 700 | 0 | |a CANCER-COVID-19 THROMBOSIS COLLABORATIVE GROUP, endorsed by VAS-European Independent Foundation in Angiology/Vascular Medicine, UEMS Vascular Medicine/Angiology and European Society of Vascular Medicine, and supported by the Balkan Working Group for Prevention and Treatment of Venous Thromboembolism and Hellenic Association of Lung Cancer |e verfasserin |4 aut | |
| 700 | 1 | |a Antic, Darko |e investigator |4 oth | |
| 700 | 1 | |a Blinc, Ales |e investigator |4 oth | |
| 700 | 1 | |a Boc, Vinko |e investigator |4 oth | |
| 700 | 1 | |a Boccardo, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Brodmann, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Carpentier, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Celovska, Denisa |e investigator |4 oth | |
| 700 | 1 | |a De Marchi, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Dimitrov, Gabriel |e investigator |4 oth | |
| 700 | 1 | |a Farkas, Katalin |e investigator |4 oth | |
| 700 | 1 | |a Fionik, Olga |e investigator |4 oth | |
| 700 | 1 | |a Fyta, Eleni |e investigator |4 oth | |
| 700 | 1 | |a Gkiozos, Ioannis |e investigator |4 oth | |
| 700 | 1 | |a Gottsater, Anders |e investigator |4 oth | |
| 700 | 1 | |a Gresele, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Hamade, Amer |e investigator |4 oth | |
| 700 | 1 | |a Heiss, Christian |e investigator |4 oth | |
| 700 | 1 | |a Karahan, Oguz |e investigator |4 oth | |
| 700 | 1 | |a Karakatsanis, Stamatis |e investigator |4 oth | |
| 700 | 1 | |a Kavousi, Maryam |e investigator |4 oth | |
| 700 | 1 | |a Kollias, Anastasios |e investigator |4 oth | |
| 700 | 1 | |a Kolossvary, Endre |e investigator |4 oth | |
| 700 | 1 | |a Kotteas, Elias |e investigator |4 oth | |
| 700 | 1 | |a Kozak, Matija |e investigator |4 oth | |
| 700 | 1 | |a Kroon, Abraham |e investigator |4 oth | |
| 700 | 1 | |a Kubat, Emre |e investigator |4 oth | |
| 700 | 1 | |a Lefkou, Eleftheria |e investigator |4 oth | |
| 700 | 1 | |a Lessani, Gianfranco |e investigator |4 oth | |
| 700 | 1 | |a Manu, Chris |e investigator |4 oth | |
| 700 | 1 | |a Mazzolai, Lucia |e investigator |4 oth | |
| 700 | 1 | |a Milic, Dragan |e investigator |4 oth | |
| 700 | 1 | |a Nancheva, Jasminka |e investigator |4 oth | |
| 700 | 1 | |a Pantazopoulos, Kosmas |e investigator |4 oth | |
| 700 | 1 | |a Patriarcheas, Vasileios |e investigator |4 oth | |
| 700 | 1 | |a Pazvanska, Evelina |e investigator |4 oth | |
| 700 | 1 | |a Pecsvarady, Zsolt |e investigator |4 oth | |
| 700 | 1 | |a Pillon, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Prior, Manilo |e investigator |4 oth | |
| 700 | 1 | |a Ptohis, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Quere, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Righini, Marc |e investigator |4 oth | |
| 700 | 1 | |a Roztocil, Karel |e investigator |4 oth | |
| 700 | 1 | |a Schernthaner, Gerit-Holger |e investigator |4 oth | |
| 700 | 1 | |a Schlager, Oliver |e investigator |4 oth | |
| 700 | 1 | |a Sieron, Aleksander |e investigator |4 oth | |
| 700 | 1 | |a Sprynger, Muriel |e investigator |4 oth | |
| 700 | 1 | |a Stanek, Agata |e investigator |4 oth | |
| 700 | 1 | |a Stojkovski, Igor |e investigator |4 oth | |
| 700 | 1 | |a Viera, Stvrtinova |e investigator |4 oth | |
| 700 | 1 | |a Suput, Dusan |e investigator |4 oth | |
| 700 | 1 | |a Syrigos, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Trontzas, Ioannis |e investigator |4 oth | |
| 700 | 1 | |a Vasic, Dragan |e investigator |4 oth | |
| 700 | 1 | |a Visona, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Xhepa, Sokol |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 42(2022), 7 vom: 26. Juli, Seite 3261-3274 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:7 |g day:26 |g month:07 |g pages:3261-3274 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.15815 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 7 |b 26 |c 07 |h 3261-3274 | ||